Mustafa Fattah is a medical fellow with the NBC News Health and Medical Unit.
Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday. The findings add to a growing body of evidence that the GLP-1 drugs, which also include Novo Nordisk’s Ozempic and Wegovy, have benefits beyond diabetes and weight loss.
Anu Lala, an advanced heart failure and transplant cardiologist at Mount Sinai Fuster Heart Hospital in New York City, said of patients with heart failure. “It’s improved the symptoms of heart failure. It improves the functional capacity of what these patients are now able to do. It improves their quality of life.” Lala said she is already using the medications with her own patients. “These individuals are just markedly short of breath,” said Lala, who was not involved with the research.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Savannah Sellers: I Learned I Have PCOS During a Fertility AssessmentSavannah Sellers is an NBC News correspondent and an anchor for NBC News NOW.
Baca lebih lajut »
Sudanese Army Chief Al-Burhan survives drone assassination attemptAbdel Fattah Al-Burhan had been attending a ceremony near Port Sudan.
Baca lebih lajut »
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager saysYuri Khodjamirian, fund manager at Tema ETFs, says there's a 'valuation opportunity' in biotech stocks at the moment — but also warned of risks.
Baca lebih lajut »
Lilly King and More Olympic Swimmers Reveal If They Pee in the PoolLilly King, Zach Harting and more Olympic swimmers are ready to be honest about some athlete’s peeing habits in the pool
Baca lebih lajut »
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatmentsQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but come 'too soon,' one analyst said.
Baca lebih lajut »
Amazon, Apple, Eli Lilly: Here's Morgan Stanley's earnings playbookAmazon, Apple, Eli Lilly: Here's Morgan Stanley's earnings playbook
Baca lebih lajut »